Lucia Del Mastro
About
Lucia Del Mastro is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Lucia Del Mastro has authored 332 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 240 papers in Oncology, 134 papers in Cancer Research and 93 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Lucia Del Mastro's work include Breast Cancer Treatment Studies (118 papers), Cancer Treatment and Pharmacology (99 papers) and HER2/EGFR in Cancer Research (75 papers). Lucia Del Mastro is often cited by papers focused on Breast Cancer Treatment Studies (118 papers), Cancer Treatment and Pharmacology (99 papers) and HER2/EGFR in Cancer Research (75 papers). Lucia Del Mastro collaborates with scholars based in Italy, Belgium and United States. Lucia Del Mastro's co-authors include Matteo Lambertini, Ornella Garrone, Marco Venturini, P. Pronzato, Francesca Poggio, M. Venturini, Fabio Puglisi, Claudia Bighin, Marcello Ceppi and Massimo Costantini and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Lucia Del Mastro
314 papers receiving 8.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Lucia Del Mastro Italy | 48 | 5.3k | 2.5k | 1.8k | 1.7k | 1.6k | 332 | 8.7k | ||
| Kathryn J. Ruddy United States | 44 | 4.1k 0.8× | 1.6k 0.6× | 1.7k 0.9× | 1.3k 0.7× | 1.3k 0.8× | 324 | 8.7k | ||
| Patricia G. Moorman United States | 41 | 4.8k 0.9× | 3.3k 1.3× | 1.1k 0.6× | 809 0.5× | 2.0k 1.3× | 135 | 8.7k | ||
| Fedro A. Peccatori Italy | 49 | 4.7k 0.9× | 1.4k 0.6× | 2.8k 1.6× | 806 0.5× | 901 0.6× | 260 | 8.7k | ||
| R. Kreienberg Germany | 54 | 4.3k 0.8× | 3.4k 1.4× | 1.0k 0.6× | 1.3k 0.8× | 934 0.6× | 434 | 10.6k | ||
| Olivia Pagani Switzerland | 42 | 3.4k 0.6× | 1.8k 0.7× | 795 0.4× | 1.5k 0.9× | 1.3k 0.8× | 159 | 5.5k | ||
| Lene Mellemkjær Denmark | 55 | 2.6k 0.5× | 1.4k 0.6× | 953 0.5× | 1.5k 0.9× | 1.8k 1.1× | 209 | 11.4k | ||
| Kathleen E. Malone United States | 63 | 7.2k 1.3× | 4.0k 1.6× | 1.7k 1.0× | 1.2k 0.7× | 3.9k 2.5× | 221 | 12.3k | ||
| Ellen Warner Canada | 40 | 3.6k 0.7× | 2.2k 0.9× | 819 0.5× | 1.3k 0.7× | 2.7k 1.8× | 198 | 8.3k | ||
| Michael S. Simon United States | 49 | 3.8k 0.7× | 1.9k 0.8× | 1.6k 0.9× | 574 0.3× | 2.0k 1.3× | 261 | 7.7k | ||
| Diane C. Bodurka United States | 54 | 3.4k 0.6× | 1.8k 0.7× | 987 0.6× | 1.1k 0.6× | 635 0.4× | 210 | 10.7k |
Countries citing papers authored by Lucia Del Mastro
Since
Specialization
Citations
This map shows the geographic impact of Lucia Del Mastro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucia Del Mastro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucia Del Mastro more than expected).
Fields of papers citing papers by Lucia Del Mastro
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Lucia Del Mastro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucia Del Mastro. The network helps show where Lucia Del Mastro may publish in the future.
Co-authorship network of co-authors of Lucia Del Mastro
This figure shows the co-authorship network connecting the top 25 collaborators of Lucia Del Mastro. A scholar is included among the top collaborators of Lucia Del Mastro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lucia Del Mastro. Lucia Del Mastro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Arecco, Luca, Elisa Agostinetto, Maria Alice Franzoi, et al.. (2025). Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance. ESMO Open. 10(5). 105057–105057.
2.
Arecco, Luca, Eva Blondeaux, Marco Bruzzone, et al.. (2025). Prognostic implications of risk definitions from the monarchE and NATALEE trials. JNCI Journal of the National Cancer Institute. 117(6). 1198–1208.
3.
Blondeaux, Eva, Claudia Bighin, Stefania Russo, et al.. (2024). Abstract PO4-04-05: HER2 immunohistochemistry (IHC) expression in HER2-positive (HER2-pos) metastatic breast cancer (mBC): clinical and prognostic differences between IHC 2+ and IHC 3+ populations. Cancer Research. 84(9_Supplement). PO4–4.
4.
Conté, Pierfranco, Maria Vittoria Dieci, Giancarlo Bisagni, et al.. (2024). A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.. Journal of Clinical Oncology. 42(17_suppl). LBA500–LBA500.
5.
Massarotti, Claudia, Anjeza Xholli, Ambrogio P. Londero, et al.. (2024). Menopausal symptoms in breast cancer survivors on adjuvant endocrine therapy compared with those of menopausal women. Maturitas. 191. 108143–108143.
6.
Maïo, Massimo Di, Claudia Bighin, Francesco Schettini, et al.. (2023). Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study. The Breast. 72. 103583–103583.
7.
Boutros, Andrea, Enrica T. Tanda, Fabio Catalano, et al.. (2023). Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis. European Journal of Cancer. 188. 64–79.
8.
Cardinali, Bárbara, Patrizia Piccioli, Simona Coco, et al.. (2023). 83P Exoxomes and miRNA in breast cancer cancerogenesis: A case-control study. ESMO Open. 8(1). 101306–101306.
9.
Arx, Claudia von, Pietro De Placido, Michelino De Laurentiis, et al.. (2022). The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treatment Reviews. 113. 102500–102500.
10.
Arecco, Luca, Eva Blondeaux, Marco Bruzzone, et al.. (2022). Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Human Reproduction. 37(5). 954–968.
11.
Poggio, Francesca, Marco Tagliamento, Davide Soldato, et al.. (2020). Update on the Management of Breast Cancer during Pregnancy. Cancers. 12(12). 3616–3616.
12.
Blondeaux, Eva, Francesca Poggio, & Lucia Del Mastro. (2019). Role of dose-dense chemotherapy in high-risk early breast cancer. Current Opinion in Oncology. 31(6). 480–485.
13.
Lambertini, Matteo, Francesca Poggio, Marco Bruzzone, et al.. (2019). Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial. International Journal of Cancer. 147(1). 160–169.
14.
Lambertini, Matteo, Arlindo R. Ferreira, Antonio Di Meglio, et al.. (2017). Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study. Clinical Breast Cancer. 17(8). 601–610.e2.
15.
Martel, Samuel, Marco Bruzzone, Marcello Ceppi, et al.. (2017). Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews. 62. 123–132.
16.
Poggio, Francesca, Marcello Ceppi, Matteo Lambertini, et al.. (2017). Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis. The Breast. 33. 104–108.
17.
Schettini, Francesco, Giuseppe Buono, Cinzia Cardalesi, et al.. (2016). Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. Cancer Treatment Reviews. 46. 20–26.
18.
Mastro, Lucia Del, Matteo Lambertini, Claudia Bighin, et al.. (2012). Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. Expert Review of Anticancer Therapy. 12(11). 1391–1405.
19.
Mastro, Lucia Del, S. Giraudi, Alessia Levaggi, & P. Pronzato. (2011). Medical approaches to preservation of fertility in female cancer patients. Expert Opinion on Pharmacotherapy. 12(3). 387–396.
20.
Venturini, M., Claudia Bighin, S. Monfardini, et al.. (2005). Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Research and Treatment. 95(1). 45–53.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Kathryn J. Ruddy Breakdown of academic impact, for papers by Patricia G. Moorman Breakdown of academic impact, for papers by Fedro A. Peccatori Breakdown of academic impact, for papers by R. Kreienberg Breakdown of academic impact, for papers by Olivia Pagani Breakdown of academic impact, for papers by Lene Mellemkjær Breakdown of academic impact, for papers by Kathleen E. Malone Breakdown of academic impact, for papers by Ellen Warner Breakdown of academic impact, for papers by Michael S. Simon Breakdown of academic impact, for papers by Diane C. Bodurka